The past, present and future of antifolates in the treatment of Plasmodium falciparum infection

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1043-1054

  Nzila, Alexis ^a,b,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antimalarials; Dihydrofolate reductase; Dihydropteroate synthase; Folate; Malaria

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; AMINOPTERIN; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CLOCIGUANIL; COTRIMOXAZOLE; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROPTEROATE SYNTHASE INHIBITOR; FANSIDAR; FOLIC ACID ANTAGONIST; KELFIPRIM; MALOPRIM; METAKELFIN; METHOTREXATE; NEW DRUG; PROGUANIL; PYRIMETHAMINE; QUININE DERIVATIVE; SULFADIAZINE; SULFADIMETHOXINE; SULFADOXINE; SULFAFURAZOLE; SULFALENE; SULFAMETOXYDIAZINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; MUTATIONAL ANALYSIS; NONHUMAN; PARASITOSIS; PLASMODIUM FALCIPARUM; REVIEW; ANIMAL; DRUG EFFECT; DRUG RESISTANCE;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 33748755472     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl104     Document Type: Review

References (138)

1. Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol 2001; 113: 579-89.
2. Mitchell HK, Snell EE, Williams RJ. The concentration of folic acid. J Am Chem Soc 1941; 63: 2284.
3. Angier RB, Boothe JH, Hutchings BL et al. Synthesis of a compound identical with the L. casei factor isolates from liver. Science 1945; 102: 227-8.
4. Hanes FM. Diagnostic criteria and resistance to therapy in the sprue syndrome. Am J Med Sc 1942; 204: 436-43.
5. Davidson LSP, Girdwood RH, Innes EM. Folate acid in treatment of sprue syndrome. Lancet 1947; i:511-5.
6. Farber S, Diamond L, Mercer RD. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948; 238: 787.
7. Jackson RC. Antifolate drugs. Past and future perspectives. In: Jackman A, ed. Antifolate Drugs in Cancer Therapy. Totawa: Human Press, 1999; 1-12.
8. Greenwood D. Conflicts of interest: The genesis of synthetic antimalarial agents in peace and war. J Antimicrob Chemother 1995; 36: 857-72.
9. Masters PA, O'Bryan TA, Zurfo J et al. Trimethoprimsulfamethoxazole revisited. Arch Intern Med 2003; 163: 402-10.
10. Smith CL, Powell KR. Review of the sulfonamides and trimethoprim. Pediatr Rev 2000; 21: 368-71.
11. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74: 730-4.
12. Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1991; 66: 1260-9.
13. Curd FRS, Davey DG, Rose FL. Study on synthetic antimalarial drugs. X. Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 1945; 39: 208-16.
14. Carrington HC, Crowther AF, Davey DG et al. A metabolite of paludrine with high antimalarial activity. Nature 1951; 168: 1080.
15. Petersen E. Malaria chemoprophylaxis: When should we use it and what are the options? Expert Rev Anti Infect Ther 2004; 2: 119-32.
16. Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 2001; 33: 381-5.
17. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33: 226-34.
18. Wernsdorfer WH. Chemoprophylaxis of malaria: Underlying principles and their realization. Med Trop (Mars) 1990; 50: 119-24.
19. Peters W, Malaria. Chemoprophylaxis and chemotherapy. Br Med J 1971; 2: 95-8.
20. Onori E, Majori G. Recent acquisitions on chemotherapy and chemoprophylaxis of malaria. Ann 1st Supef Sanita 1989; 25: 659-73.
21. Kain KG. Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria. BioDrugs 2003; 17: 23-8.
22. Watkins WM, Brandling-Bennett AD, Oloo AJ et al. Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. Lancet 1987; i: 125-8.
23. Knight DJ, Peters W. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. Ann Trop Med Parasitol 1980; 74: 393-404.
24. Laing AB. Studies on the chemotherapy of malaria. (III). Treatment of falciparum malaria in the Gambia, with BRL 50216 (4,6-diamino-(3, 4-dichlorobenzyloxy)-1,2-dihydro-2 2-dimethyl-1,3,5-triazine hydrochloride) alone and in combination with sulphonamides. Trans R Soc Trop Med Hyg 1974; 68: 133-8.
25. Rieckmann KH, Yeo AE, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Mad Hyg 1996; 90: 568-71.
26. Hitchings GH, Elion GB, Falco EA et al. Antagonists of nucleic acid derivatives. i. the Lactobacillus casei model. J Biol Chem 1950; 183: 1-9.
27. Falco EA, Goodwin LG, Hitchings GH at al. 2:4 diaminopyridimidines - a new series of antimalarials. Br J Pharmacol Chemother 1951; 6: 185-200.
28. Zhang K, Rathod PK. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 2002; 296: 545-7.
29. Nirmalan N, Sims PF, Hyde JE. Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. Mol Biochem Parasitol 2004; 136: 63-70.
30. Michel R. Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophyiaxis of malaria. Med Trop (Mars) 1968; 28: 488-94.
31. Fromm E, Wittmann J. Derivate des p-nitrophenols. Deutsch Chem Gas 1908; 41: 2264-73.
32. Buttle G, Stephenson D, Smith S. The treatment of streptococcal infections in mice with 4:4 diaminodiphenylsulfone. Lancet 1937; i: 1331-4.
33. Fourneau E, Trefouel J, Nitti F. Streptococcique des derives sulfures organiques. C R Acad Sci 1937; 204: 1763-6.
34. Rieckmann KH, Brewer GJ, Powell RD. Effects of diaphenylsulphone (dapsone) against Plasmodium vivax of South West Pacific origin. Trans R Soc Trop Med Hyq 1968; 62: 649-53.
35. Sheehy TW, Reba RC, Neff TA et al. Supplemental sulfone (dapsone) therapy. Use in treatment of chloroquine-resistant falciparum malaria. Arch Intern Med 1967; 119: 561-6.
36. Britton WJ, Lockwood DN. Leprosy. Lancet 2004; 363: 1209-19.
37. Watson J. Pneumocystis carinii: Where are we now? J HIV Ther 2002; 7: 8-12.
38. Wolf R, Matz H, Orion E et al. Dapsone. Dermatol Online J 2002; 8: 2.
39. McGregor IA, Williams K, Goodwin LG. Pyrimethamine and sulphadiazine in treatment of malaria. Br Med J 1963; 5359: 728-9.
40. Hurly MG. Potentiation of pyrimethamine by sulphadiazine in human malaria. Trans R Soc Trop Med Hyg 1959; 53: 412-13.
41. Powell RD, DeGowin RL, McNamara JV. Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum. Ann Trop Med Parasitol 1967; 61: 396-408.
42. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Mad Hyg 1993; 87: 75-8.
43. Winstanley P, Watkins W, Muhia D et al. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 1997; 91: 322-7.
44. Segal HE, Chinvanthananond P, Laixuthai B et al. Comparison of diaminodiphenylsulphonepyrimethamine and sulfadoxine-pyrimethamine combinations in the treatment of falciparum malaria in Thailand. Trans R Soc Trop Med Hyg 1975; 69: 139-42.
45. Peters W. Resistance in human malaria III: Dihydrofolate reductase inhibitors. In: Chemotherapy and Drug Resistance in Malaria. London: Academic Press Limited, 1987; 593-827.
46. Thera MA, Sehdev PS, Coulibaly D et al. Impact of trimethoprimsulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005; 192: 1823-9.
47. Khalil IF, Ronn AM, Alifrangis M et al. Response of Plasmodium falciparum to cotrimoxazole therapy: Relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes. Am J Trop Med Hyg 2005; 73: 174-7.
48. Hamel MJ, Holtz T, Mkandala C et al.: Efficacy of trimethoprimsulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am J Trop Med Hyg 2005; 73: 609-15.
49. Fehintola FA, Adedeji AA, Sowunmi A. Comparative efficacy of chloroquine and cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children. Cent Afr J Med 2002; 48: 101-5.
50. Omar SA, Bakari A, Owiti A et al. Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans R Soc Trop Med Hyg 2001; 95: 657-60.
51. Black RH. Malaria in the Australian army in South Vietnam: Successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. Med J Aust 1973; 1: 1265-70.
52. Shanks GD, Edstein MD, Suriyamongkol V et al.: Malaria chemoprophylaxis using proguanil/dapsone combinations on the ThaiCambodian border. Am J Trop Med Hyg 1992; 46: 643-8.
53. Mutabingwa TK, Maxwell CA, Sia IG et al. A trial of proguanildapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans R Soc Trop Med Hyg 2001; 95: 433-8.
54. Krudsood S, Imwong M, Wilairatana P et al. Artesunate-dapsone-proguanil treatment of falciparum malaria: Genotypic determinants of therapeutic response. Trans R Soc Trop Med Hyg 2005; 99: 142-9.
55. Winstanley PA, Mberu EK, Szwandt IS et al. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother 1995; 39: 948-52.
56. Watkins WM, Mberu EK, Winstanley PA et al. The efficacy of antifolate antimalarial combination in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997; 13: 459-64.
57. Nzila AM, Nduati E, Mberu EK et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000; 181: 2023-8.
58. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185: 380-8.
59. Nzila-Mounda A, Mberu EK, Sibley CH et al. Kenyan Plasmodium falciparum field isolates: Correlation between pyrimethamine and cloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 1998; 42: 164-9.
60. Bukirwa H, Garner P, Critchley J. Chlorproguanil-dapsone for treating uncomplicated malaria. Cochrane Database Syst Rev 2004; Issue 4: CD004387.
61. Mutabingwa T, Nzila A, Mberu E et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358: 1218-23.
62. Wootton D, Opara H, Dube-mbeye Q et al. A dose-ranging, phase II trial of chlorproguanil dapsone with three doses of artesunate for the treatment of acute uncomplicated P. falciparum, malaria. Acta Trop 2005; 95: S189-90.
63. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Nati Acad Sci USA 1988; 85: 9114-18.
64. Peterson DS, Milhous WK, Wollems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87: 3018-22.
65. Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 1990; 87: 3014-17.
66. Hyde JE. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 1990; 48: 45-59.
67. Toyoda T, Brobey RK, Sano G et al. Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Biochem Biophys Res Commun 1997; 235: 515-19.
68. Sirawaraporn W, Sathitkul T, Sirawaraporn R et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997; 94: 1124-9.
69. Giraldo LE, Acosta MC, Labrada LA et al. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia. Am J Trop Med Hyg 1998; 59: 124-8.
70. Sibley CH, Hyde JE, Sims PF et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next? Trends Parasitol 2001; 17: 582-8.
71. Triglia T, Wang P, Sims PF et al. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J 1998; 17: 3807-15.
72. Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1994; 91: 7149-53.
73. Triglia T, Cowman AF. The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist Updat 1999; 2: 15-19.
74. Wang P, Read M, Sims PF et al. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol 1997; 23: 979-86.
75. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005; 57: 117-45.
76. Wilairatana P, Kyle DE, Looareesuwan S et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann Trop Med Parasitol 1997; 91: 125-32.
77. Hastings MD, Bates SJ, Blackstone EA et al. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg 2002; 96: 674-6.
78. Nzila A, Ochong E, Nduati E et al. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans R Soc Trop Med Hyg 2005; 99: 341-6.
79. Ochong E, Nzila A, Kimani S et al. Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/ pyrimethamine-resistant area in Africa. Malar J 2003; 2: 46.
80. Roper C, Pearce R, Nair S et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305: 1124.
81. Hunt SY, Rezvani BB, Sibley CH. Novel alleles of Plasmodium falciparum dhfr that confer resistance to chlorcycloguanil. Mol Biochem Parasitol 2005; 139: 25-32.
82. Bates SJ, Winstanley PA, Watkins WM et al. Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. J Infect Dis 2004; 190: 1783-92.
83. Chusacultanachai S, Thiensathit P, Tarnchompoo B et al. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol 2002; 120: 61-72.
84. Hankins EG, Warhurst DC, Sibley CH. Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol Biochem Parasitol 2001; 117: 91-102.
85. Ferlan JT, Mookherjee S, Okezie IN et al. Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: Analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210. Mol Biochem Parasitol 2001; 113: 139-50.
86. Lau H, Ferlan JT, Brophy VH et al. Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa. Antimicrob Agents Chemother 2001; 45: 187-95.
87. Kinyanjui SM, Mberu EK, Winstanley PA et al. The antimalarial triazine WR99210 and the prodrug PS-15: Folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am J Trop Med Hyg 1999; 60: 943-7.
88. Watkins WM, Sixsmith DG, Chulay JD et al. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol Biochem Parasitol 1985; 14: 55-61.
89. Carter JY, Loolpapit MP, Lema OE et al. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg 2005; 73: 166-70.
90. van Hensbroek MB, Morris-Jones S, Meisner S et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89: 672-6.
91. Wang P, Sims PF, Hyde JE. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 1997; 115: 223-30.
92. Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999; 59: 2532-5.
93. Nzila A, Kokwaro G, Winstanley P et al. Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. Trends Parasitol 2004; 20: 109-12.
94. Nzila A, Mberu E, Bray P et al. Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother 2003; 47: 2108-12.
95. Sowunmi A, Adedeji AA, Fateye BA et al. Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. Parasite 2004; 11: 317-23.
96. Sowunmi A, Fehintola FA, Adedeji AA et al. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop Med Int Health 2004; 9: 606-14.
97. Sowunmi A, Adedeji AA, Fateye BA et al. Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria. Ann Trop Med Parasitol 2004; 98: 873-8.
98. Fury MG, Krug LM, Azzoli CG et al. A phase 1 clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol 2006; 57: 671-7.
99. Canfield CJ, Milhous WK, Ager AL et al. PS-15: A potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993; 49: 121-6.
100. Yeo AE, Rieckmann KH. The activity of PS-15 in combination with sulfamethoxazole. Trop Med Parasitol 1994; 45: 136-7.
101. Edstein MD, Bahr S, Kotecka B et al. In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand. Antimicrob Agents Chemother 1997; 41: 2300-1.
102. Jensen NP, Ager AL, Bliss RA et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 2001; 44:3925-31.
103. Yuthavong Y, Yuvaniyama J, Chitnumsub P et al. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: Structural basis for antifolate resistance and development of effective inhibitors. Parasitology 2005; 130: 249-59.
104. Fidock DA, Rosenthal PJ, Croft SL et al. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3: 509-20.
105. Chitnumsub P, Yavaniyama J, Vanichtanankul J et al. Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. Acta Crystallogr D Biol Crystallogr 2004; 60: 780-3.
106. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003; 10: 357-65.
107. Sirawaraporn W, Sirawaraporn R, Yongkiettrakul S et al. Mutational analysis of Plasmodium falciparum dihydrofolate reductase: The role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. Mol Biochem Parasitol 2002; 121: 185-93.
108. Sardarian A, Douglas KT, Read M et al. Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. Org Biomol Chem 2003; 1: 960-4.
109. Kamchonwongpaisan S, Quarrell R, Charoensetakul N et al. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J Med Chem 2004; 47: 673-80.
110. Tarnchompoo B, Sirichaiwat C, Phupong W et al. Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. J Med Chem 2002; 45: 1244-52.
111. Sirichaiwat C, Intaraudom C, Kamchonwongpaisan S et al. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: Their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem 2004; 47: 345-54.
112. Yuthavong Y. Basis for antifolate action and resistance in malaria. Microbes Infect 2002; 4: 175-82.
113. Yuthavong Y, Vilaivan T, Chareonsethakul N et al. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. J Med Chem 2000; 43: 2738-44.
114. Kamchonwongpaisan S, Vanichtanankul J, Tarnchompoo B et al. Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase. Anal Chem 2005; 77: 1222-7.
115. Ommeh S, Nduati E, Mberu E et al. In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparum. Antimicrob Agents Chemother 2004; 48: 3711-14.
116. Parenti MD, Pacchioni S, Ferrari AM et al. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. J Med Chem 2004; 47: 4258-67.
117. Agarwal A, Srivastava K, Puri SK et al. Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents. Bioorg Med Chem Lett 2005; 15: 531-3.
118. Agarwal A, Srivastava K, Puri SK et al. Synthesis of substituted indole derivatives as a new class of antimalarial agents. Bioorg Med Chem Lett 2005; 15: 3133-6.
119. Agarwal A, Srivastava K, Puri SK et al. Synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents. Bioorg Med Chem 2005; 13: 4645-50.
120. Agarwal A, Srivastava K, Puri SK et al. Antimalarial activity and synthesis of new trisubstituted pyrimidines. Bioorg Med Chem Lett 2005; 15: 3130-2.
121. Agarwal A, Srivastava K, Puri SK et al. Antimalarial activity of 2,4,6-trisubstituted pyrimidines. Bioorg Med Chem Lett 2005; 15: 1881-3.
122. Nzila A, Ward SA, Marsh K et al. Comparative folate metabolism in humans and malaria parasites (part II): Activities as yet untargeted or specific to Plasmodium. Trends Parasitol 2005; 21: 334-9.
123. Nzila A, Ward SA, Marsh K et al. Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 2005; 21: 292-8.
124. Patel OG, Mberu EK, Nzila AM et al. Sulfa drugs strike more than once. Trends Parasitol 2004; 20: 1-3.
125. Dieckmann A, Jung A. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol Biochem Parasitol 1986; 19: 143-7.
126. Bertino JR, Goker E, Gorlick R et al. Resistance mechanisms to methotrexate in tumors. Oncologist 1996; 1: 223-6.
127. Golenser J, Casuto D, Pollack Y. Plasmodium falciparum: In vitro induction of resistance to aminopterin. Exp Parasitol 1981; 52: 371-7.
128. Fidock DA, Wellems TE. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 1997; 94: 10931-6.
129. Walter RD, Bergmann B, Kansy M et al. Pyrimethamin-resistant Plasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines. Parasitol Res 1991; 77: 346-50.
130. Nduati E, Hunt S, Kamau EM et al. 2,4-Diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: A novel class of antimalarials. Antimicrob Agents Chemother 2005; 49: 3652-7.
131. Rathod PK, Leffers NP, Young RD. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob Agents Chemother 1992; 36: 704-11.
132. Rathod PK, Khatri A, Hubbert T et al. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 1989; 33: 1090-4.
133. Rathod PK, Khosla M, Gassis S et al. Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum. Antimicrob Agents Chemother 1994; 38: 2871-6.
134. Krungkrai J, Krungkrai SR, Phakanont K. Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol 1992; 43: 1295-301.
135. Jiang L, Lee PC, White J et al. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob Agents Chemother 2000; 44: 1047-50.
136. Queen SA, Jagt DL, Reyes P. In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism. Antimicrob Agents Chemother 1990; 34: 1393-8.
137. Rathod PK, Reshmi S. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase. Antimicrob Agents Chemother 1994; 38: 476-80.
138. Cowman AF, Crabb BS. Functional genomics: Identifying drug targets for parasitic diseases. Trends Parasitol 2003; 19: 538-43.